PTC THERAPEUTICS, INC. (PTCT) Form 8-K — Aug 28, 2026
PTC Therapeutics entered into an asset purchase agreement on August 25, 2026 to acquire ST-920, a one-time administered AAV gene therapy candidate for Fabry disease, from Sangamo Therapeutics for an upfront payment of $111 million plus up to $100 million in contingent milestone payments. The milestones consist of $80 million upon FDA accelerated approval of a biologics license application for ST-920 based on Sangamo's Phase 1/2 STAAR study and $20 million upon full approval. PTC was selected as the winning bidder for the asset in a competitive auction conducted in Sangamo's Chapter 11 bankruptcy case.
Key figures
- Deal Value Usd
- up to $211 million total ($111 million upfront plus up to $100 million in contingent milestones)
- Milestone Total
- up to $100 million
- Upfront Payment
- $111 million
- Outside Closing Date
- October 15, 2026
- Milestone Full Approval
- $20 million
- Bankruptcy Court Hearing Date
- September 10, 2026
- Milestone Accelerated Approval
- $80 million
Price after filing
Close on the filing date to close N calendar days later (from $70.09). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.